19 completed, 12 withdrawn, 9 active not recruiting, 9 recruiting. 24 Phase 1, 24 Phase 2, 5 Early Phase 1, 5 Not applicable, 2 Phase 3.
Follow this condition Literature Review of Prognostic Stage IV Breast Cancer AJCC v8 trials Research Report on Prognostic Stage IV Breast Cancer AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer Ipilimumab, Pembrolizumab, Vaccine Therapy - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | Phase 1 | Recruiting | Emory University | 18 | 2025-12-02 | 2026-01-26 |
| Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer Minoxidil, Quality-of-Life Assessment, Questionnaire Administration - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | Early Phase 1 | Recruiting | Ohio State University Comprehensive Cancer Center | 50 | 2023-03-01 | 2026-03-10 |
| In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Poly ICLC, Radiation Therapy - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 1 | Active not recruiting | University of Southern California | 14 | 2023-01-09 | 2026-06-18 |
| Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer Anti-HER2/HER3 Dendritic Cell Vaccine, Pembrolizumab - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Malignant Neoplasm in the Brain | Phase 2 | Recruiting | Roswell Park Cancer Institute | 23 | 2022-12-19 | 2026-07-21 |
| SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer Carboplatin, Pembrolizumab, Transferrin Receptor-Targeted Liposomal p53 cDNA - Anatomic Stage IV Breast Cancer AJCC v8, Breast Inflammatory Carcinoma | Phase 1 | Withdrawn | Northwestern University | 2022-11-10 | 2022-11-15 | |
| Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy Y-90 SIR-Spheres, Yttrium-90 Microsphere Radioembolization, Systemic Therapy - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 2 | Withdrawn | Emory University | 2022-08-17 | 2024-01-19 | |
| Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast Cancer Best Practice, Biopsy, Biospecimen Collection - Advanced Breast Adenocarcinoma, Advanced HER2-Negative Breast Carcinoma | Not applicable | Withdrawn | City of Hope Medical Center | 2022-07-03 | 2022-06-09 | |
| Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax Atezolizumab, Cabozantinib S-malate, Nab-paclitaxel - Advanced Breast Carcinoma, Advanced Endometrial Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 43 | 2022-04-29 | 2026-07-16 |
| Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer Carboplatin, Docetaxel, Fulvestrant - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8 | Phase 1 / Phase 2 | Active not recruiting | Jonsson Comprehensive Cancer Center | 18 | 2022-04-07 | 2026-05-11 |
| A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic Cancer Health Education, Questionnaire Administration - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Not applicable | Active not recruiting | Ohio State University Comprehensive Cancer Center | 243 | 2022-03-30 | 2026-04-13 |
| Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer Carboplatin, Cyclophosphamide, Doxorubicin - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2022-03-11 | 2024-10-24 | |
| Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer Dostarlimab, Niraparib, Biopsy - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Active not recruiting | University of Washington | 18 | 2021-10-18 | 2026-08-20 |
| CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer Oncolytic Virus CF33-expressing hNIS/Anti-PD-L1 Antibody - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma | Phase 1 | Active not recruiting | City of Hope Medical Center | 9 | 2021-10-18 | 2026-04-17 |
| Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel Cimetidine, Dexamethasone, Diphenhydramine - Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 | Phase 2 / Phase 3 | Completed | Ohio State University Comprehensive Cancer Center | 130 | 2021-10-07 | 2025-08-20 |
| Fluciclovine and PSMA PET/CT for the Classification and Improved Staging of Invasive Lobular Breast Cancer Computed Tomography, Fluciclovine F18, Gallium Ga 68 Gozetotide - Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Lobular Carcinoma | Phase 1 | Completed | Emory University | 20 | 2021-07-16 | 2025-01-17 |
| Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases Sacituzumab Govitecan - Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma | Phase 2 | Active not recruiting | SWOG Cancer Research Network | 44 | 2021-06-08 | 2026-05-06 |
| Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer Abexinostat Tosylate, Fulvestrant, Palbociclib - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Phase 1 | Withdrawn | Pamela Munster | 2021-03-31 | 2021-05-18 | |
| Pembrolizumab and Tamoxifen With or Without Vorinostat for the Treatment of Estrogen Receptor Positive Breast Cancer Pembrolizumab, Tamoxifen, Vorinostat - Anatomic Stage IV Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8 | Phase 2 | Terminated | University of California, San Francisco | 1 | 2021-03-11 | 2023-08-31 |
| Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial Bintrafusp Alfa, Immunocytokine NHS-IL12, Radiation Therapy - Anatomic Stage IV Breast Cancer AJCC v8, Hormone Receptor Positive Breast Adenocarcinoma | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2021-03-07 | 2023-12-27 | |
| 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases Computed Tomography, 18F-FMAU, Multiparametric Magnetic Resonance Imaging - Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Early Phase 1 | Completed | University of Southern California | 10 | 2021-02-15 | 2024-05-24 |
Showing 20 of 56. Sign in to see all of them.
Breast Neoplasms (28) · Triple Negative Breast Neoplasms (16) · Brain Neoplasms (7) · Neoplasm Metastasis (7) · Lung Neoplasms (6) · Ovarian Neoplasms (6) · Melanoma (4) · Colorectal Neoplasms (3) · Fallopian Tube Neoplasms (3) · Pancreatic Neoplasms (3) · Prostatic Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (2) · Carcinoma, Renal Cell (2) · Glioma (2) · Inflammatory Breast Neoplasms (2)
Neoplasms (47) · Neoplasms by Site (46) · Skin Diseases (43) · Skin and Connective Tissue Diseases (43) · Breast Diseases (42) · Breast Neoplasms (14) · Neoplasms by Histologic Type (10) · Neoplastic Processes (8) · Pathologic Processes (8) · Pathological Conditions, Signs and Symptoms (8) · Urogenital Diseases (8) · Brain Diseases (7) · Central Nervous System Diseases (7) · Central Nervous System Neoplasms (7) · Digestive System Diseases (7)
pembrolizumab (7) · Fulvestrant (6) · Taxes (6) · Carboplatin (5) · Letrozole (5) · palbociclib (5) · Magnetic Resonance Spectroscopy (4) · Paclitaxel (4) · Radiation (4) · Radiotherapy (4) · abemaciclib (4) · bintrafusp alfa protein, human (4) · Albumin-Bound Paclitaxel (3) · Anastrozole (3) · Biopsy (3)
M.D. Anderson Cancer Center (15) · Emory University (5) · Ohio State University Comprehensive Cancer Center (5) · City of Hope Medical Center (4) · Mayo Clinic (3) · National Cancer Institute (NCI) (3) · Roswell Park Cancer Institute (3) · SWOG Cancer Research Network (2) · University of California, San Francisco (2) · University of Southern California (2) · Wake Forest University Health Sciences (2) · Academic and Community Cancer Research United (1) · ECOG-ACRIN Cancer Research Group (1) · Jonsson Comprehensive Cancer Center (1) · Mridula George, MD (1)
United States (50) · Puerto Rico (3) · Canada (1) · Guam (1) · Ireland (1) · Saudi Arabia (1) · South Korea (1)
Banu Arun (2) · Meghan Karuturi (2) · Roy Strowd, MD (2) · Senthilkumar Damodaran (2) · Agnieszka K Witkiewicz (1) · Alison M Schram (1) · Amy J Chien, MD (1) · Andrew J Brenner (1) · Apostolia M Tsimberidou (1) · Azadeh Nasrazad, MD,PHD (1) · Brenda J. Ernst, M.D. (1) · Brittany L Dulmage, MD (1) · Ciara C O'Sullivan (1) · Daniel G Stover, MD (1) · David M Schuster, MD (1)
PMID 32379297, PMID 35602670, PMID 35728046, PMID 36008574, PMID 36269154, PMID 36351402, PMID 36658425, PMID 37023705, PMID 37704753, PMID 38028143, PMID 38106014, PMID 38976035, PMID 39865083, PMID 40506447, PMID 40933893, PMID 40939237, PMID 41271741, PMID 41576303, PMID 42868120
P30CA138292 (5), P30CA016672 (3), P30CA033572 (3), P30CA012197 (2), P30CA014089 (1), P30CA015083 (1), P30CA016058 (1), P30CA060553 (1), P30CA072720 (1), R21CA259985 (1), R44CA257278 (1), U10CA180820 (1), U10CA180868 (1), U10CA180888 (1), UG1CA189974 (1)